AR106466A1 - Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents
Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vihInfo
- Publication number
- AR106466A1 AR106466A1 ARP160103249A ARP160103249A AR106466A1 AR 106466 A1 AR106466 A1 AR 106466A1 AR P160103249 A ARP160103249 A AR P160103249A AR P160103249 A ARP160103249 A AR P160103249A AR 106466 A1 AR106466 A1 AR 106466A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- domain
- formula
- variable
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C07K16/1145—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente memoria se proporcionan que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH o uno o más receptores de células T, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales que tienen una orientación cruzada y en donde un segundo par de polipéptidos que forman la proteína de unión posee un solo dominio variable. También se proporcionan en la presente memoria métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de tales proteínas de unión para el tratamiento y/o la prevención de VIH / SIDA. Reivindicación 1: Una proteína de unión que comprende cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH, en donde una primera cadena polipeptídica comprende una estructura representada por la fórmula: VL₂-L₁-VL₁-L₂-CL [1]; una segunda cadena polipeptídica comprende una estructura representada por la fórmula: VH₁-L₃-VH₂-L₄-CH₁ [2]; una tercera cadena polipeptídica comprende una estructura representada por la fórmula: VH₃-CH₁ [3]; y una cuarta cadena polipeptídica comprende una estructura representada por la fórmula: VL₃-CL [4]; en donde VL₁ es un primer dominio variable de cadena ligera de inmunoglobulina; VL₂ es un segundo dominio variable de cadena ligera de inmunoglobulina; VL₃ es un tercer dominio variable de cadena ligera de inmunoglobulina; VH₁ es un primer dominio variable de cadena pesada de inmunoglobulina; VH₂ es un segundo dominio variable de cadena pesada de inmunoglobulina; VH₃ es un tercer dominio variable de cadena pesada de inmunoglobulina; CL es un dominio constante de cadena ligera de inmunoglobulina; CH₁ es un dominio constante de cadena pesada CH₁ de inmunoglobulina; y L₁, L₂, L₃, y L₄ son conectores aminoacídicos; y en donde el polipéptido de fórmula [1] y el polipéptido de fórmula [2] forman un par de cadena ligera-cadena pesada entrecruzadas.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246113P | 2015-10-25 | 2015-10-25 | |
| EP16305211 | 2016-02-24 | ||
| US201662322029P | 2016-04-13 | 2016-04-13 | |
| US201662331169P | 2016-05-03 | 2016-05-03 | |
| PCT/US2016/058540 WO2017074878A1 (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106466A1 true AR106466A1 (es) | 2018-01-17 |
Family
ID=55588187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103249A AR106466A1 (es) | 2015-10-25 | 2016-10-25 | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20190054182A1 (es) |
| EP (2) | EP3819310A1 (es) |
| JP (3) | JP7169190B2 (es) |
| KR (1) | KR102687212B1 (es) |
| CN (4) | CN116789841A (es) |
| AR (1) | AR106466A1 (es) |
| AU (2) | AU2016347058B2 (es) |
| BR (1) | BR112018008011A2 (es) |
| CA (1) | CA3002664A1 (es) |
| CL (1) | CL2018001065A1 (es) |
| CO (1) | CO2018005337A2 (es) |
| CR (1) | CR20180288A (es) |
| DO (1) | DOP2018000102A (es) |
| EA (1) | EA201891028A1 (es) |
| ES (1) | ES2894304T3 (es) |
| HR (1) | HRP20211528T1 (es) |
| HU (1) | HUE056608T2 (es) |
| IL (2) | IL301140A (es) |
| MA (1) | MA42641A1 (es) |
| MX (2) | MX2018005048A (es) |
| MY (1) | MY192278A (es) |
| PE (1) | PE20181167A1 (es) |
| PH (1) | PH12018500873A1 (es) |
| PL (1) | PL3365366T3 (es) |
| RS (1) | RS62437B1 (es) |
| SG (1) | SG11201803324VA (es) |
| SI (1) | SI3365366T1 (es) |
| TW (3) | TW202442675A (es) |
| UY (1) | UY36965A (es) |
| WO (1) | WO2017074878A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052132B1 (en) | 2013-09-30 | 2020-07-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| WO2019135921A1 (en) * | 2017-12-21 | 2019-07-11 | Aaron Diamond Aids Research Center | Bispecific hiv-1-neutralizing antibodies |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| EP3110844B1 (en) * | 2014-02-28 | 2020-02-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| PE20181167A1 (es) * | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
| EP3371214A1 (en) * | 2015-11-03 | 2018-09-12 | THE UNITED STATES OF AMERICA, represented by the S | Neutralizing antibodies to hiv-1 gp41 and their use |
| MX2018012566A (es) | 2016-04-13 | 2019-08-05 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes. |
| FI3443006T3 (fi) * | 2016-04-13 | 2023-10-23 | Sanofi Sa | Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| BR112019020235A2 (pt) * | 2017-03-27 | 2020-04-22 | The Wistar Institute Of Anatomy And Biology | molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo. |
| AU2018290228B2 (en) * | 2017-06-21 | 2021-07-01 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV gp120 and CD3 |
| JP7036909B2 (ja) * | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| WO2019123262A1 (en) * | 2017-12-18 | 2019-06-27 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| KR102737364B1 (ko) | 2018-01-12 | 2024-12-05 | 젠자임 코포레이션 | 폴리펩티드의 정량화를 위한 방법 |
| WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| MX2021004147A (es) * | 2018-10-09 | 2021-09-08 | Sanofi Sa | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral. |
| WO2020106713A1 (en) * | 2018-11-21 | 2020-05-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| MY208876A (en) * | 2019-04-09 | 2025-06-05 | Sanofi Sa | Trispecific binding proteins, methods, and uses thereof |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| MX2022004881A (es) | 2019-10-25 | 2022-05-16 | Sanofi Sa | Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas. |
| US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| CN116157416A (zh) * | 2020-08-25 | 2023-05-23 | 吉利德科学公司 | 靶向hiv的多特异性抗原结合分子及其使用方法 |
| AU2022354068A1 (en) * | 2021-09-29 | 2024-04-18 | Modex Therapeutics, Inc. | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof |
| CN118317979A (zh) * | 2021-09-29 | 2024-07-09 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| CN118660907A (zh) * | 2021-09-29 | 2024-09-17 | 摩德斯医疗股份有限公司 | 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| WO2025108551A1 (en) | 2023-11-23 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025109206A1 (en) | 2023-11-22 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| US20250376537A1 (en) | 2024-05-17 | 2025-12-11 | Sanofi | Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Ｈｉｖ感染細胞に殺作用する抗体異種結合体 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| IL156955A0 (en) | 2001-01-17 | 2004-02-08 | Genecraft Inc | Binding domain-immunoglobulin fusion proteins |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| EP1641827A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| TW201008580A (en) | 2008-06-03 | 2010-03-01 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| PL2580243T3 (pl) | 2010-06-09 | 2020-05-18 | Genmab A/S | Przeciwciała przeciwko ludzkiemu CD38 |
| EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | 多特异性fab融合蛋白及其使用方法 |
| DK2710033T3 (da) * | 2011-05-17 | 2021-03-08 | Univ Rockefeller | Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf |
| US9475862B2 (en) | 2011-11-07 | 2016-10-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing GP41 antibodies and their use |
| EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| EP2788376B1 (en) | 2011-12-08 | 2018-10-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP3401337A1 (en) * | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| US9951106B2 (en) | 2012-12-04 | 2018-04-24 | University Of Maryland, Baltimore | Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb |
| HK1213481A1 (zh) | 2012-12-13 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | Dna抗体构建体及其使用方法 |
| US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US20140242077A1 (en) * | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| NZ708182A (en) * | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| JP2016517277A (ja) | 2013-03-15 | 2016-06-16 | アッヴィ・インコーポレイテッド | ＴＮＦαに対して指向された二重特異的結合タンパク質 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| NZ720161A (en) | 2013-11-04 | 2022-07-29 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
| MX385936B (es) | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| BR112017004270B1 (pt) | 2014-09-04 | 2023-03-07 | Stemcell Technologies Inc | Método de ativação de células t ou células nk |
| KR102680151B1 (ko) | 2015-01-23 | 2024-07-03 | 사노피 | 항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체 |
| CA2986237A1 (en) | 2015-05-20 | 2016-11-24 | Quantum-Si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
| US10654943B2 (en) | 2015-06-02 | 2020-05-19 | The Rockefeller University | Tri-specific antibodies for HIV therapy |
| EA201890782A1 (ru) | 2015-09-22 | 2018-09-28 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способ перенацеливания t-клеток для лечения инфекции hiv |
| PE20181167A1 (es) | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| EA202091898A1 (ru) | 2015-12-15 | 2021-06-22 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
| MX2018012566A (es) | 2016-04-13 | 2019-08-05 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes. |
| FI3443006T3 (fi) | 2016-04-13 | 2023-10-23 | Sanofi Sa | Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja |
| EP3575319A4 (en) | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| BR112019020235A2 (pt) | 2017-03-27 | 2020-04-22 | The Wistar Institute Of Anatomy And Biology | molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo. |
| JP7036909B2 (ja) | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| MX2021004147A (es) | 2018-10-09 | 2021-09-08 | Sanofi Sa | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral. |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en not_active Ceased
- 2016-10-24 BR BR112018008011-0A patent/BR112018008011A2/en not_active Application Discontinuation
- 2016-10-24 KR KR1020187014534A patent/KR102687212B1/ko active Active
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-25 TW TW113100534A patent/TW202442675A/zh unknown
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP7724814B2/ja active Active
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
- 2024-11-26 US US18/960,890 patent/US20250312475A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106466A1 (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| CO2018012107A2 (es) | Proteínas de unión triespecíficas y/o trivalentes | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| EA201792572A1 (ru) | Антитела к ox40 и их применение | |
| CY1123917T1 (el) | Ομοιοπολικα συνδεδεμενα δισωματα που εχουν ανοσοδραστικοτητα me pd-1 και lag-3, και μεθοδοι χρησης αυτων | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
| EA201692476A1 (ru) | Модифицированные антигенсвязывающие полипептидные конструкции и их применение | |
| BR112018073761A2 (pt) | proteínas de ligação ao cd3 de fragmento variável de cadeia única | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| MX395074B (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos | |
| EA201692459A1 (ru) | Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
| ECSP18039758A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| AR118602A1 (es) | Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih |